Solid Biosciences (SLDB) Income from Continuing Operations (2017 - 2026)
Solid Biosciences (SLDB) reported Income from Continuing Operations of 60675000.0 for Q1 2026, down 60.13% on a YoY basis from 152167390.3 in Q1 2025, and down 28.13% sequentially from 47356000.0 in Q4 2025.
Solid Biosciences (SLDB) Income from Continuing Operations (2017 - 2026) Analysis & Trends
Solid Biosciences (SLDB) has 10 years of Income from Continuing Operations data on file, last reported at 60675000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations fell 60.13% year-over-year to 60675000.0; the trailing twelve-month figure through Mar 2026 stood at 197360000.0 (down 40.29% YoY), and the FY2025 full-year result was 359739000.0, down 43.35% from the prior year.
- Income from Continuing Operations declined to 60675000.0 in Q1 2026, from 47356000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 20592000.0 in Q3 2022 to a low of 196598000.0 in Q4 2022.
- A 5-year average of 43396411.76 and a median of 32078000.0 in 2023 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations soared 87.45% in 2023 and tumbled 70.15% in 2024, its largest moves.
- Tracing SLDB's Income from Continuing Operations over 5 years: stood at 196598000.0 in 2022, then soared by 87.45% to 24667000.0 in 2023, then plunged by 70.15% to 41970000.0 in 2024, then slipped by 12.83% to 47356000.0 in 2025, then declined by 28.13% to 60675000.0 in 2026.
- Business Quant data shows SLDB's Income from Continuing Operations at 60675000.0 in Q1 2026, 47356000.0 in Q4 2025, and 47129000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Solid Biosciences | 529.40 Mn | 529.40 Mn | - | -60.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -60.68 Mn |
| Dec 31, 2025 | -47.36 Mn |
| Sep 30, 2025 | -47.13 Mn |
| Jun 30, 2025 | -42.20 Mn |
| Mar 31, 2025 | -37.89 Mn |
| Dec 31, 2024 | -41.97 Mn |
| Sep 30, 2024 | -32.94 Mn |
| Jun 30, 2024 | -27.89 Mn |
| Mar 31, 2024 | -26.98 Mn |
| Dec 31, 2023 | -24.67 Mn |
| Sep 30, 2023 | -21.26 Mn |
| Jun 30, 2023 | -26.95 Mn |
| Mar 31, 2023 | -32.08 Mn |
| Dec 31, 2022 | -196.60 Mn |
| Sep 30, 2022 | -20.59 Mn |
| Jun 30, 2022 | -25.21 Mn |
| Mar 31, 2022 | -25.37 Mn |
| Dec 31, 2021 | -147.22 Mn |
| Sep 30, 2021 | -18.05 Mn |
| Jun 30, 2021 | -18.70 Mn |